These five companies posted double-digit declines on the week.
News & Analysis: Vical
Is there hope for Vical after abandoning Allovectin?
These five stocks got moving last week.
Q2 revenue of blah, blah, blah. Forget the numbers. Here's what you really need to know from Vical's Q2 results.
Market-lagging returns could be written in this 2-star stock.
The immune system attacks the injection site.
These five companies soared this past week.
Does the potential here outweigh the risk?
3 events biotech investors should be watching in 2013.
Just the facts, Fool.